potential indications for glp-1 receptor agonists keep expanding Diabetes vs GLP-1 for Weight Loss: What's Changing for Patients and Pharmacies? Glucagon Like Peptide-1 Receptor Agonists

Figure 2 The neuroprotective effects of GLP-1 receptor agonists (RAs) such as liraglutide and exendin-4 have been demonstrated in numerous clinical trials related to diabetic neurological complications, including stroke and cognitive impairment (7578)

Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women

Patients typically experience reductions in HbA1c (glycated haemoglobin) of approximately 1.01.5% (1116 mmol/mol) when added to existing therapy, with some agents achieving even greater reductions

At therapeutic doses, GLP-1 medications can delay gastric emptying by roughly 3050% during the early phases of treatment , which contributes to reduced post-meal glucose spikes and improved satiety signaling

More than ten medications are already FDA approved for weight loss